Showing results (21-30 of 422) with videos related to
Sort By:
Pageof 43
Current Opinion in Pharmacology|July 23, 2008
Targeted therapy for cancer using PARP inhibitorsChristopher J Lord, Alan AshworthCarcinogenesis|May 27, 2005
BRCA1 and BRCA2 as ovarian cancer susceptibility genesHeidi M Sowter, Alan AshworthScience (New York, N.Y.)|March 18, 2017
PARP inhibitors: Synthetic lethality in the clinicChristopher J Lord, Alan AshworthNature Reviews. Drug Discovery|March 11, 2017
Marked for death: targeting epigenetic changes in cancerSophia Xiao Pfister, Alan AshworthNature Medicine|November 9, 2013
Mechanisms of resistance to therapies targeting BRCA-mutant cancersChristopher J Lord, Alan AshworthInteractive Cardiovascular and Thoracic Surgery|June 24, 2010
Does the prophylactic administration of N-acetylcysteine prevent acute kidney injury following cardiac surgery?Alan Ashworth, Stephen T WebbNature Reviews. Clinical Oncology|June 30, 2018
Synthetic lethal therapies for cancer: what's next after PARP inhibitors?Alan Ashworth, Christopher J LordClinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 19, 2009
Bringing DNA repair in tumors into focusChristopher J Lord, Alan AshworthCurrent Biology : CB|January 28, 2003
X-chromosome inactivation: X marks the spot for BRCA1Caroline Stone, Nuala McCabe, Alan AshworthNature Reviews. Cancer|October 29, 2004
Hallmarks of 'BRCAness' in sporadic cancersNicholas Turner, Andrew Tutt, Alan AshworthPageof 43